Cybin Signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003)

CANNANNEW REPORT

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has signed a… Read More…..

Excerpt only …
READ MORE BELOW
Source : Cybin Signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003)

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.